Most of our predictions, including the CNR2 inhibitor GW405833, the UGCG inhibitor DL-PDMP, the TSPO antagonist PK11195, and the MAPK8/JNK inhibitor AS601245, downregulated the expression of genes induced during the cell cycle, implicating effects on neuroblastoma cell growth (Fig. 4d). This evidence concerns the gene MAPK8 and neuroblastoma.